NCT04024462 2026-02-20A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast CancerHoffmann-La RochePhase 3 Completed200 enrolled 16 charts
NCT07416409 2026-02-18Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast CancerDeraya UniversityCompleted80 enrolled